Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yunnan TBH Biotech is a China-based biotechnology and functional ingredient company focused on the research, production, and commercialization of white kidney bean extract, particularly alpha-amylase inhibitory protein (α-AI). The company positions itself as an early and leading participant in China’s white kidney bean extract industry and supplies ingredient solutions for nutrition, health food, and related commercial applications. Its core commercial product is a patented white kidney bean extract marketed for starch-blocking, weight management, and blood sugar support applications. TBH Biotech also works with agricultural and academic partners on germplasm improvement, cultivation, and industrial standards for white kidney beans. The business appears to operate more like a nutraceutical/health-ingredient manufacturer than a drug-development biotech with a clinical therapeutic pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tianbao Bio-Tech.